Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1986 Jun;52(3):725–729. doi: 10.1128/iai.52.3.725-729.1986

Effect of polymyxin B and colimycin on induction of plasminogen antiactivator by lipopolysaccharide in human endothelial cell culture.

F Dubor, A M Dosne, L A Chedid
PMCID: PMC260918  PMID: 3011672

Abstract

The effect of lipopolysaccharide (LPS) on the production of fibrinolytic inhibitor by human endothelial cells was determined because results of previous experiments have shown us that it is possible to stimulate this synthesis with muramyl dipeptide. Treatment of these cells with LPS resulted in a marked enhancement of fibrinolytic inhibitor, as estimated in a urokinase-induced fibrinolysis assay. A dose-response curve was obtained for LPS concentrations ranging from 10 to 1,000 ng/ml, thus demonstrating the great sensitivity of these cells. This inhibitor did not reduce plasmin activity and formed complexes with high- and low-molecular-weight urokinase as visualized by fibrin enzymography on sodium dodecyl sulfate-polyacrylamide electrophoretic gels. The molecular weight of this inhibitor was estimated to be 54 to 58 kilodaltons. These findings led us to conclude that LPS stimulates formation of a plasminogen antiactivator. This LPS effect could be suppressed by polymyxin B and colimycin. The stimulatory effect of muramyl dipeptide required doses which were at least 1,000 times greater than those of LPS and was not decreased by polymyxin B. These results show the possibility of independent modulation of plasminogen antiactivator production at the endothelial level, which could be important in endotoxemia. Under these conditions colimycin might have an additional advantage for clinical use because of its ability to prevent fibrinolytic inhibition.

Full text

PDF
725

Images in this article

727Image
on p.727

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chapman H. A., Jr, Vavrin Z., Hibbs J. B., Jr Coordinate expression of macrophage procoagulant and fibrinolytic activity in vitro and in vivo. J Immunol. 1983 Jan;130(1):261–266. [PubMed] [Google Scholar]
  2. Chapman H. A., Jr, Vavrin Z., Hibbs J. B., Jr Macrophage fibrinolytic activity: identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor. Cell. 1982 Mar;28(3):653–662. doi: 10.1016/0092-8674(82)90220-3. [DOI] [PubMed] [Google Scholar]
  3. Colucci M., Paramo J. A., Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest. 1985 Mar;75(3):818–824. doi: 10.1172/JCI111777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Corrigan J. J., Jr, Bell B. M. Endotoxin-induced intravascular coagulation: prevention with polymyxin B sulfate. J Lab Clin Med. 1971 May;77(5):802–810. [PubMed] [Google Scholar]
  5. Dosne A. M., Dubor F., Terrier M., Dupuy E., Chedid L. Increased synthesis of fibrinolytic inhibitor induced by muramyl dipeptide derivatives in human cultured endothelial cells. Int J Immunopharmacol. 1985;7(2):225–230. doi: 10.1016/0192-0561(85)90030-x. [DOI] [PubMed] [Google Scholar]
  6. Dosne A. M., Dupuy E., Bodevin E. Production of a fibrinolytic inhibitor by cultured endothelial cells derived from human umbilical vein. Thromb Res. 1978 Mar;12(3):377–387. doi: 10.1016/0049-3848(78)90309-2. [DOI] [PubMed] [Google Scholar]
  7. Dosne A. M., Legrand C., Bauvois B., Bodevin E., Caen J. P. Comparative degradation of adenylnucleotides by cultured endothelial cells and fibroblasts. Biochem Biophys Res Commun. 1978 Nov 14;85(1):183–189. doi: 10.1016/s0006-291x(78)80027-8. [DOI] [PubMed] [Google Scholar]
  8. Drapier J. C., Lemaire G., Petit J. F. Regulation of plasminogen activator secretion in mouse peritoneal macrophages. II. Inhibition by immunomodulators of bacterial origin. Int J Immunopharmacol. 1982;4(1):21–34. doi: 10.1016/0192-0561(82)90005-4. [DOI] [PubMed] [Google Scholar]
  9. Emeis J. J., van Hinsbergh V. W., Verheijen J. H., Wijngaards G. Inhibition of tissue-type plasminogen activator by conditioned medium from cultured human and porcine vascular endothelial cells. Biochem Biophys Res Commun. 1983 Jan 27;110(2):392–398. doi: 10.1016/0006-291x(83)91161-0. [DOI] [PubMed] [Google Scholar]
  10. Erickson L. A., Ginsberg M. H., Loskutoff D. J. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest. 1984 Oct;74(4):1465–1472. doi: 10.1172/JCI111559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Esnard F., Dupuy E., Dosne A. M., Bodevin E. Partial characterization of a fibrinolytic inhibitor produced by cultured endothelial cells derived from human umbilical vein. Thromb Haemost. 1982 Apr 30;47(2):128–131. [PubMed] [Google Scholar]
  12. Galdal K. S. Thromboplastin synthesis in endothelial cells. Haemostasis. 1984;14(5):378–385. doi: 10.1159/000215095. [DOI] [PubMed] [Google Scholar]
  13. Golder J. P., Stephens R. W. Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activators. Eur J Biochem. 1983 Nov 15;136(3):517–522. doi: 10.1111/j.1432-1033.1983.tb07771.x. [DOI] [PubMed] [Google Scholar]
  14. Granelli-Piperno A., Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med. 1978 Jul 1;148(1):223–234. doi: 10.1084/jem.148.1.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Harlan J. M., Harker L. A., Striker G. E., Weaver L. J. Effects of lipopolysaccharide on human endothelial cells in culture. Thromb Res. 1983 Jan 1;29(1):15–26. doi: 10.1016/0049-3848(83)90121-4. [DOI] [PubMed] [Google Scholar]
  16. Jacobs D. M., Morrison D. C. Inhibition of the mitogenic response to lipopolysaccharide (LPS) in mouse spleen cells by polymyxin B. J Immunol. 1977 Jan;118(1):21–27. [PubMed] [Google Scholar]
  17. Jaffe E. A., Nachman R. L., Becker C. G., Minick C. R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973 Nov;52(11):2745–2756. doi: 10.1172/JCI107470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Levin E. G. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci U S A. 1983 Nov;80(22):6804–6808. doi: 10.1073/pnas.80.22.6804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Loskutoff D. J., van Mourik J. A., Erickson L. A., Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci U S A. 1983 May;80(10):2956–2960. doi: 10.1073/pnas.80.10.2956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Morrison D. C., Jacobs D. M. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry. 1976 Oct;13(10):813–818. doi: 10.1016/0019-2791(76)90181-6. [DOI] [PubMed] [Google Scholar]
  21. Morrison D. C., Jacobs D. M. Inhibition of lipopolysaccharide-initiated activation of serum complement by polymyxin B. Infect Immun. 1976 Jan;13(1):298–301. doi: 10.1128/iai.13.1.298-301.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Morrison D. C., Ulevitch R. J. The effects of bacterial endotoxins on host mediation systems. A review. Am J Pathol. 1978 Nov;93(2):526–618. [PMC free article] [PubMed] [Google Scholar]
  23. Nel A. E., Wooten M. W., Goldschmidt-Clermont P. J., Miller P. J., Stevenson H. C., Galbraith R. M. Polymyxin B causes coordinate inhibition of phorbol ester-induced C-kinase activity and proliferation of B lymphocytes. Biochem Biophys Res Commun. 1985 May 16;128(3):1364–1372. doi: 10.1016/0006-291x(85)91091-5. [DOI] [PubMed] [Google Scholar]
  24. Palmer J. D., Rifkind D. Neutralization of the hemodynamic effects of endotoxin by polymyxin B. Surg Gynecol Obstet. 1974 May;138(5):755–759. [PubMed] [Google Scholar]
  25. Philips M., Juul A. G., Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta. 1984 Nov 6;802(1):99–110. doi: 10.1016/0304-4165(84)90039-4. [DOI] [PubMed] [Google Scholar]
  26. Quesenberry P. J., Gimbrone M. A., Jr Vascular endothelium as a regulator of granulopoiesis: production of colony-stimulating activity by cultured human endothelial cells. Blood. 1980 Dec;56(6):1060–1067. [PubMed] [Google Scholar]
  27. Rifkind D., Hill R. B., Jr Neutralization of the Shwartzman reactions by polymyxins B. J Immunol. 1967 Sep;99(3):564–569. [PubMed] [Google Scholar]
  28. Schöffel U., Shiga J., Mittermayer C. The proliferation-inhibiting effect of endotoxin on human endothelial cells in culture and its possible implication in states of shock. Circ Shock. 1982;9(5):499–508. [PubMed] [Google Scholar]
  29. Warren J. R. Polymyxin B suppresses the endotoxin inhibition of concanavalin a-mediated erythrocyte agglutination. Infect Immun. 1982 Feb;35(2):594–599. doi: 10.1128/iai.35.2.594-599.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. van Mourik J. A., Lawrence D. A., Loskutoff D. J. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem. 1984 Dec 10;259(23):14914–14921. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES